AbbVie Inc. (ABBV) fundamental analysis

From the Sep 26, 2026 report · Read the full report

Annual income statement

Fiscal year	Revenue	Growth	Gross margin	Operating margin	Net margin	Free cash flow	Diluted EPS
Dec 31, 2025	61.16B	8.6%	70.2%	32.8%	6.9%	17.82B	2.36
Dec 31, 2024	56.33B	3.7%	70.0%	21.1%	7.6%	17.83B	2.39
Dec 31, 2023	54.32B	-6.4%	62.4%	24.9%	9.0%	22.06B	2.72
Dec 31, 2022	58.05B	—	70.0%	32.4%	20.4%	24.25B	6.63

Balance sheet

Jun 30, 2026

Cash and short-term investments: 6.57B
Total debt: 70.82B
Shareholders' equity: -5.94B

Against its sector

	ABBV	Sector median
Forward P/E	16.4	—
Net margin	9.8%	—
Revenue growth	10.2%	—

From the Sep 26, 2026 report

ABBV's fundamental analysis reveals a company with strong cash flow generation despite negative equity metrics. The company's TTM PE ratio of 74.46 is historically high due to temporary one-time costs (e.g., restructuring, legal settlements), while the forward PE ratio of 16.26 reflects strong future growth expectations. The PEG ratio of 0.54 indicates undervaluation relative to growth. Operating cash flow remains strong at $3.44B in Q2 2026, with FCF covering 99% of dividends. The company maintains a 2.61% dividend yield, with FCF ($3.11B Q2 2026) exceeding dividend payments (99% coverage). Balance sheet metrics show concern with a current ratio of 0.81 (below 1.0) and negative working capital (-$7.97B), but these are mitigated by strong operating cash flow and interest coverage of 6.7x.

Frequently asked questions

How fast is ABBV revenue growing?

AbbVie Inc. reported revenue of 61.16B in the fiscal year ended Dec 31, 2025, 8.6% more than the year before.

Data as of Sep 29, 2026. Sources: Yahoo Finance (prices, financial statements and analysts' estimates) and the U.S. Treasury (10-year yield). Indicators and valuation are computed without AI.

AI-generated informational content. Not financial advice or a personalised investment recommendation. Investing involves risk, including loss of capital.

Every week, in your inbox

Rating changes, the highest-conviction stocks and the week's best research. Free.